Osborne Clarke advises investors on Tagworks Pharmaceuticals $65 Million Series A Financing

Osborne Clarke has advised the syndicate of investors led by Gilde Healthcare and Ysios Capital and with participation from Novartis Venture Fund, New Enterprise Associates (NEA) and Lightstone Ventures on the $65 million Series A financing of Tagworks Pharmaceuticals BV, the pioneer of Click-to-Release chemistry designed to deliver more effective and safer systemic therapies.

Tagworks’ unique platform enables on-target activation of antibody-drug conjugates (ADCs) and immunomodulators, as well as off-target deactivation of radiopharmaceuticals. The financing will support the advancement of TGW101, Tagworks’ lead click-cleavable ADC program, and the company’s proprietary Click-to-Release platform.

The Osborne Clarke core deal team consisted of Partner Herke van Hulst, Senior Associate Wouter Kok and Associate Levi Schutz and further included partner/ civil-law notary Cars Jan van Gool, Senior Associate Arlette Vrolijk, Tax partner Job van der Pol, Associate Sjoerd Waagmeester, TMC/IP partner Coen Barneveld Binkhuysen and Senior Associate Sophie den Held, GDPR Partner Joanne Zaaijer, Associate Philippe Helder, Employment, Pensions and Incentive Partner Jorgo Tsiris and Senior Associate Wyke Schilstra.

Osborne Clarke has a market-leading international venture capital practice and is widely recognised as a leading European law firm for companies operating in the life science and healthcare sector. Its sector team has a strong track record of providing highly sophisticated advice to investors and biotech clients on cutting-edge issues, across multiple service lines. They work with blue chip venture capital firms, the biggest pharma and medical devices companies in the market.